Systemic sclerosis (scleroderma) trials in Romania

In Romania 8 Also abroad 213

8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Bucharest, Cluj-Napoca, Iași
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 3Not yet taking people in Romania
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Beneﬁted from Continued Treatment.
Where
Bucharest
People
340 worldwide
Run by
AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00
Phase 2Taking people
Evaluation of MTX-474 in Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Where
Brasov, Bucharest, Timisoara
Age
18 years and over
People
36 worldwide
Run by
Mediar Therapeutics Inc.
See details and how to join2025-523288-39-00 · EU 2025-523288-39-00
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Bucharest, Cluj-Napoca, Constanta
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 2Taking people
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Where
Brasov, Bucharest, Timișoara
Age
18 years and over
People
85 worldwide
Run by
Mediar Therapeutics
See details and how to joinNCT07287670
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Bucharest
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Bucharest, Cluj-Napoca
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
No phaseTaking people
EFESO: Study on Juvenile Onset Eosinophilic Fasciitis
Where
Cluj-Napoca
Age
Up to 18 years
People
20 worldwide
Run by
Meyer Children's Hospital IRCCS
See details and how to joinNCT07348263